India’s Lupin Set For Global Generics Growth; Logs 53 Percent Profit Jump In Q2
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Indian drug maker Lupin said it was poised to grow further in the global generics market as it reported a 53 percent jump in consolidated quarterly net profit, driven by a strong across-the-board performance